Desvenlafaxine

Desvenlafaxine, sold under the brand name Pristiq among others, is a medication used to treat major depressive disorder. It is recommended that the need for further treatment be occasionally reassessed. It appears less effective than its parent compound venlafaxine. It is taken by mouth. Desvenlafaxine, sold under the brand name Pristiq among others, is a medication used to treat major depressive disorder. It is recommended that the need for further treatment be occasionally reassessed. It appears less effective than its parent compound venlafaxine. It is taken by mouth. Common side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems. Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure. A withdrawal syndrome may occur if the dose is rapidly decreased. It is unclear if use during pregnancy or breastfeeding is safe. It is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class. Desvenlafaxine was approved for medical use in the United States in 2008. Use in Europe was declined in 2009. In the United States the wholesale cost is about 25.20 USD per month. In 2016, it was the 272nd most prescribed medication in the United States, with more than a million prescriptions. Desvenlafaxine is primarily used as a treatment for major depressive disorder. Use has only been studied up to 8 weeks. It, however, appears less effective than venlafaxine. Doses of 50-400 mg/day appear effective for major depressive disorder, although no additional benefit was demonstrated at doses greater than 50 mg/day, and adverse events and discontinuations were more frequent at higher doses. Desvenlafaxine improves the HAM-D17 score and measures of well being such as the Sheehan Disability Scale (SDS) and 5-item World Health Organization Well-Being Index (WHO-5). Frequency of adverse effects: Very common adverse effects include: Common adverse effects include: